Table 2.
Base case results representing an annual cohort from England (primary outcomes)
| Strategy | 1(2) | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| Incremental costs vs Strategy 1(1) [£ Thousands] | ||||||||
| Diagnosis | 48.9 | 662.7 | 578.5 | 599.6 | 586.0 | 636.9 | 1061.6 | 1336.6 |
| CRC prevention | 396.7 | 735.9 | 726.9 | 822.1 | 817.1 | 817.1 | 928.8 | 1065.7 |
| CRC treatment | −249.3 | −646.9 | −646.2 | −725.5 | −725.2 | −725.2 | −814.0 | −848.8 |
| EC prevention | 210.4 | 338.1 | 333.2 | 377.3 | 374.5 | 374.5 | 427.0 | 499.6 |
| EC treatment | −21.7 | −60.6 | −60.6 | −68.0 | −68.0 | −68.0 | −76.2 | −78.7 |
| Total | 384.9 | 1029.2 | 931.8 | 1005.4 | 984.5 | 1035.3 | 1527.1 | 1974.5 |
| Incremental QALYs vs Strategy 1(1) | ||||||||
| Short-term | 0 | −4.3 | −4.1 | −4.8 | −4.6 | −4.6 | −5.5 | −8.5 |
| Long-term | 63.9 | 164.0 | 163.9 | 184.0 | 183.9 | 183.9 | 206.4 | 214.8 |
| Total | 63.9 | 159.7 | 159.8 | 179.2 | 179.3 | 179.3 | 200.9 | 206.3 |
| Cost–utility | ||||||||
| ICER vs Strategy 1(1) [cost per QALY gained] | £6021 | £6444 | £5831 | £5610 | £5491 | £5774 | £7601 | £9571 |
| ICER [cost per QALY gained] | ED | D | ED | D | £5491 | D | £25106 | £82962 |
| INHB at WTP £20000/QALY vs 1(1) [QALYs] | 44.7 | 108.3 | 113.2 | 129.0 | 130.1 | 127.5 | 124.5 | 107.6 |
Key: D, dominated; EC, endometrial cancer; ED, extended dominated; WTP, willingness-to-pay.